What are your top takeaways in GU Cancers from ASTRO 2024?
6 Answers
Mednet Member
Radiation Oncology · UC San Diego
- The Presidential Symposium was outstanding. Dr. Brandon Mahal’s presentation hit on a top priority for the field, in my view: how do we improve/accelerate the implementation of advances like focal microboost for prostate cancer? RCT evidence of benefit to dose escalation is rare in rad onc. The FLA...
Mednet Member
Radiation Oncology · UPMC Hillman Cancer Center
- PARTIQoL: This phase III trial randomized 450 men with low- or intermediate-risk prostate cancer to receive definitive external beam radiation therapy with either photons (control arm) or protons (experimental arm). The radiation dose/fractionation was either conventional fractionation or moderate...
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center
- @Dr. First Last, MD, PhD presented the results of the PARTIQoL trial, a Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer. Patients with intermediate- or low-risk prostate cancer were randomized to PBT or IMRT, without hormonal therapy, stratified for inst...
Mednet Member
Radiation Oncology · St. Francis Radiation Oncology
The PARTIQoL study being negative was huge - and validates what we saw in our claims-based analyses.
Mednet Member
Radiation Oncology · Duke University Medical Center
The PARTIQoL trial can help reassure patients that they need not travel long distances to receive proton therapy for their localized prostate cancer.